口服活性
医学
药理学
风险分析(工程)
计算机科学
重症监护医学
梅德林
鉴定(生物学)
传统医学
业务
作者
Sanhu Gou,Zufang Ba,Bingqian Ren,Hui Liu,Yun Zhang,Chao Zhong,Yongxi Dong,Jingman Ni
标识
DOI:10.1016/j.apsb.2026.10.032
摘要
Peptide therapeutics occupy the space between small-molecule drugs and protein biologics, offering high target selectivity and unique access to traditionally undruggable protein–protein interaction surfaces. Oral peptide administration remains rare because gastrointestinal proteolysis, insufficient epithelial permeability, transporter-mediated efflux, and first-pass metabolism jointly limit systemic exposure. These constraints make injection the dominant clinical route and complicate long-term therapy. Clinical products validate two distinct strategies: oral semaglutide achieves systemic delivery through formulation optimization, whereas cyclosporine A, icotrokinra, and enlicitide yield orally active agents via standalone molecular optimization or combined molecular and formulation strategies. This review integrates physiological barriers, molecular modification, experimental evaluation, physicochemical space, library technologies, computational tools, and clinical evidence. It proposes the evidence-based oral-competent molecular architecture (OCMA) framework with three tiered validation layers. OCMA serves neither as a universal platform nor a binary criterion for beyond-rule-of-five chemical space. It defines three oral peptide discovery paradigms: architecture-first focused libraries, hit-first discovery followed by oralization, and drug-likeness-biased hybrid libraries. The review compares major screening platforms and establishes a staged in vitro -to- in vivo pharmacokinetic validation workflow. Routine computational support is distinguished from prospective closed-loop discovery. Reliable clinical translation of oral peptides requires coordinated multi-dimensional optimization and product-specific verification.
科研通智能强力驱动
Strongly Powered by AbleSci AI